Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
GeneDx HoldingsWGS +3.30%65 Market Cap is $2,693.6 Mil as of Aug. 27, 2026. GuruFocus rates WGS with a GF Score™ of 65/100 and a GF Value™ of $73.77 (Modestly Overvalued). The stock has 1 warning sign investors should review. Among 216 Medical Diagnostics & Research companies, GeneDx Holdings ranks better than 83.33% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). GeneDx Holdings's share price for the quarter that ended in Jun. 2026 was $68.65. GeneDx Holdings's Shares Outstanding (EOP) for the quarter that ended in Jun. 2026 was 29.8 Mil. Therefore, GeneDx Holdings's market cap for the quarter that ended in Jun. 2026 was $2,046.0 Mil.
GeneDx Holdings's quarterly market cap
declined
from Dec. 2025 ($3,803.6 Mil) to Mar. 2026 ($1,905.2 Mil) but then
increased
from Mar. 2026 ($1,905.2 Mil) to Jun. 2026 ($2,046.0 Mil).
GeneDx Holdings's annual market cap
increased
from Dec. 2023 ($71.4 Mil) to Dec. 2024 ($2,153.4 Mil) and
increased
from Dec. 2024 ($2,153.4 Mil) to Dec. 2025 ($3,803.6 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. GeneDx Holdings's Enterprise Value for Today is $2,728.4 Mil.
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
GeneDx Holdings Market Cap Related Terms
GeneDx Holdings Market Cap Historical Data
* Premium members only.
The historical data trend for GeneDx Holdings's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, GeneDx Holdings's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GeneDx Holdings Market Cap vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, GeneDx Holdings's Market Cap distribution charts can be found below:
* The bar in red indicates where GeneDx Holdings's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
GeneDx Holdings's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GeneDx Holdings (WGS) has a Market Cap of $2,693.6 Mil as of Aug. 27, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on GeneDx Holdings and its competitors. According to the industry distribution chart, GeneDx Holdings ranks #36 out of 216 companies in the Medical Diagnostics & Research industry, placing it in the top 16.7%.
Is GeneDx Holdings' Market Cap too high?
GeneDx Holdings' current Market Cap is $2,693.6 Mil. The Medical Diagnostics & Research industry median Market Cap is 63.43. GeneDx Holdings' value of $2,693.6 Mil is 4146.6% above this industry median. Based on the distribution chart, GeneDx Holdings ranks #36 out of 216 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, GeneDx Holdings has a GF Score™ of 65/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does GeneDx Holdings' Market Cap compare to NEO and CDNA?
According to the Medical Diagnostics & Research industry distribution chart, GeneDx Holdings ranks #36 out of 216 companies for Market Cap. This places GeneDx Holdings in the top 17% of its industry — outperforming the majority of peers. The industry median Market Cap is 63.43. GeneDx Holdings' value of $2,693.6 Mil is 4146.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Medical Diagnostics & Research company?
The median Market Cap among Medical Diagnostics & Research companies is 63.43, based on 216 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. GeneDx Holdings's current Market Cap of $2,693.6 Mil is 4146.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on GeneDx Holdings and its competitors. For the Medical Diagnostics & Research industry, the median Market Cap is 63.43 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GeneDx Holdings's current Market Cap is $2,693.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GeneDx Holdings stock overvalued right now?
Based on GuruFocus' analysis, GeneDx Holdings (WGS) is currently considered Modestly Overvalued. The stock's GF Value™ is $73.77, compared to a current price of $90.32 — trading 22.4% above its estimated fair value. The current Market Cap is $2,693.6 Mil and 4146.6% above the Medical Diagnostics & Research industry median of 63.43. GeneDx Holdings' overall GF Score™ is 65/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For GeneDx Holdings (WGS), the current Market Cap is $2,693.6 Mil as of Aug. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is GeneDx Holdings (WGS) Overvalued in 2026?
Based on GuruFocus' analysis, GeneDx Holdings stock appears to be overvalued.
The current stock price of $90.32 is trading 22.4% above its estimated GF Value™ of $73.77.
GuruFocus considers GeneDx Holdings to be Modestly Overvalued.
Key valuation signals for WGS:
Market Cap: $2,693.6 Mil
GF Value™: $73.77 vs. price of $90.32 (22.4% above fair value)
Industry Position: 4146.6% above the Medical Diagnostics & Research median (#36 of 216)
No single metric tells the full story. See the WGS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.
65GF Score
Get the complete analysis for WGS
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WGS has been successfully added to your 
